Mariusz A Wasik Selected Research

Immunotherapy

1/2016	Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy.
2/2009	The combination of IL-21 and IFN-alpha boosts STAT3 activation, cytotoxicity and experimental tumor therapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mariusz A Wasik Research Topics

Disease

40	Neoplasms (Cancer) 12/2023 - 01/2002
25	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 01/2019 - 11/2002
17	Lymphoma (Lymphomas) 01/2024 - 01/2002
16	T-Cell Lymphoma (Lymphoma, T Cell) 01/2024 - 05/2005
9	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 01/2013 - 05/2002
7	Leukemia 10/2023 - 04/2006
7	Carcinogenesis 01/2022 - 12/2005
5	B-Cell Lymphoma (Lymphoma, B Cell) 05/2023 - 12/2002
5	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 10/2019 - 09/2006
4	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 10/2017 - 12/2002
4	Inflammation (Inflammations) 12/2014 - 06/2011
3	Disease Progression 12/2023 - 04/2013
3	Burkitt Lymphoma (Burkitt's Lymphoma) 03/2021 - 08/2009
3	Mycosis Fungoides 12/2014 - 04/2013
2	Renal Cell Carcinoma (Grawitz Tumor) 12/2023 - 02/2009
2	Hodgkin Disease (Hodgkin's Disease) 01/2023 - 10/2017
2	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 03/2021 - 08/2009
2	Hypoxia (Hypoxemia) 10/2020 - 01/2017
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 10/2017 - 09/2003
2	Starvation 07/2016 - 09/2006
2	Dermatitis 08/2013 - 11/2011
2	Infections 09/2011 - 02/2005
2	Sezary Syndrome (Sezary Erythroderma) 06/2008 - 01/2002
1	Adenocarcinoma of Lung 01/2023
1	Adenocarcinoma 01/2023
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2021
1	Residual Neoplasm 01/2021
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2018
1	Cytokine Release Syndrome 12/2017
1	Genetic Translocation (Chromosomal Translocation) 01/2017
1	Hypersensitivity (Allergy) 01/2017

Drug/Important Bio-Agent (IBA)

14	CytokinesIBA 01/2024 - 02/2008
14	Anaplastic Lymphoma KinaseIBA 01/2022 - 01/2002
12	Phosphotransferases (Kinase)IBA 12/2023 - 12/2005
10	Proteins (Proteins, Gene)FDA Link 01/2024 - 11/2002
7	DNA (Deoxyribonucleic Acid)IBA 12/2023 - 01/2002
6	Interleukin-2 (IL2)IBA 07/2016 - 11/2002
5	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2022 - 04/2006
5	MicroRNAs (MicroRNA)IBA 01/2018 - 11/2011
4	NucleophosminIBA 01/2022 - 04/2009
4	Transforming Growth Factor beta (TGF-beta)IBA 10/2020 - 01/2002
4	Chimeric Antigen ReceptorsIBA 12/2017 - 01/2016
4	Interleukin-17 (Interleukin 17)IBA 03/2016 - 06/2011
4	Mechanistic Target of Rapamycin Complex 1IBA 12/2013 - 02/2008
3	EnzymesIBA 12/2023 - 01/2013
3	ibrutinibIBA 12/2023 - 01/2016
3	Therapeutic UsesIBA 10/2023 - 02/2009
3	Tyrosine Kinase InhibitorsIBA 01/2018 - 05/2013
3	p80(NPM-ALK) proteinIBA 01/2017 - 04/2009
3	AntibodiesIBA 01/2016 - 03/2003
3	TOR Serine-Threonine KinasesIBA 01/2016 - 05/2003
3	Messenger RNA (mRNA)IBA 06/2015 - 12/2008
3	Membrane Proteins (Integral Membrane Proteins)IBA 03/2014 - 12/2008
3	Interleukin-15 (Interleukin 15)IBA 01/2014 - 02/2008
3	Interleukin-10 (Interleukin 10)IBA 12/2013 - 06/2006
3	interleukin-21 (interleukin 21)IBA 02/2009 - 02/2008
3	Non-Receptor Type 6 Protein Tyrosine PhosphataseIBA 03/2007 - 11/2002
2	AntigensIBA 01/2024 - 05/2023
2	LigandsIBA 01/2024 - 06/2008
2	Rituximab (Mabthera)FDA Link 12/2023 - 02/2005
2	RNA (Ribonucleic Acid)IBA 01/2023 - 01/2023
2	Transforming Growth Factor beta Receptors (TGF beta Receptors)IBA 10/2020 - 01/2002
2	1,2- di- (4- sulfamidophenyl)- 4- butylpyrazolidine- 3,5- dione (DSB)IBA 10/2020 - 01/2017
2	Agammaglobulinaemia Tyrosine KinaseIBA 10/2019 - 01/2019
2	talazoparibIBA 01/2018 - 01/2017
2	olaparibIBA 01/2018 - 01/2017
2	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2017 - 09/2003
2	tisagenlecleucelIBA 01/2016 - 01/2016
2	Glucose (Dextrose)FDA LinkGeneric 01/2016 - 01/2013
2	Lactic Acid (Lactate)FDA LinkGeneric 01/2016 - 01/2013
2	Enterotoxins (Enterotoxin)IBA 07/2014 - 04/2007
2	Bacterial ToxinsIBA 08/2013 - 04/2007
2	Sirolimus (Rapamycin)FDA Link 01/2013 - 01/2011
2	Interferon Type IIBA 09/2011 - 02/2009
2	RetinoidsIBA 10/2008 - 08/2005
2	Bexarotene (LGD1069)FDA Link 10/2008 - 08/2005
2	Complementary DNA (cDNA)IBA 04/2006 - 01/2002
2	Tyrosine (L-Tyrosine)FDA Link 12/2005 - 11/2002
1	Antigen Receptors (Antigen Receptor)IBA 01/2024
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2024
1	Alkylating AgentsIBA 12/2023
1	vecabrutinibIBA 12/2023
1	Bendamustine Hydrochloride FDA Link 12/2023
1	NAD (NADH)IBA 12/2023
1	DNA Polymerase thetaIBA 10/2023
1	Immune Checkpoint ProteinsIBA 03/2021
1	Acetyl Coenzyme A (Acetyl-CoA)IBA 05/2020
1	src-Family KinasesIBA 05/2020
1	ATP Citrate (pro-S)-Lyase (Citrate Synthase, ATP)IBA 05/2020
1	Phosphatidylinositols (Phosphatidylinositol)IBA 05/2020
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2019
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 12/2018
1	fms-Like Tyrosine Kinase 3IBA 01/2018

Therapy/Procedure

13	Therapeutics 01/2023 - 02/2005
2	Drug Therapy (Chemotherapy) 01/2017 - 08/2004
2	Immunotherapy 01/2016 - 02/2009
2	Transplantation 12/2010 - 04/2006
2	Organ Transplantation 08/2005 - 05/2002
1	Nephrectomy 12/2023
1	Precision Medicine 10/2017